Stockscreener 앱 받기
2.90
1.02%
-0.03
시간 외 거래:
2.91
0.01
+0.34%
전일 마감가:
$2.93
열려 있는:
$2.93
하루 거래량:
91,423
Relative Volume:
0.43
시가총액:
$117.44M
수익:
-
순이익/손실:
$-58.75M
주가수익비율:
-0.6702
EPS:
-4.327
순현금흐름:
$-50.79M
1주 성능:
-1.69%
1개월 성능:
-24.68%
6개월 성능:
-27.50%
1년 성능:
+14.17%
1일 변동 폭
$2.86
$3.00
1주일 범위
$2.86
$3.24
52주 변동 폭
$2.23
$5.38
Onkure Therapeutics Inc Stock (OKUR) Company Profile
명칭
Onkure Therapeutics Inc
전화
(720) 307-2892
주소
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
2.90 | 117.44M | 0 | -58.75M | -50.79M | -4.327 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-30 | 개시 | Evercore ISI | Outperform |
| 2024-12-05 | 개시 | Leerink Partners | Outperform |
| 2024-10-10 | 개시 | Oppenheimer | Outperform |
| 2023-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-12-14 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | 개시 | William Blair | Outperform |
| 2023-08-28 | 개시 | H.C. Wainwright | Buy |
| 2023-07-03 | 개시 | BofA Securities | Buy |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-01-27 | 개시 | Robert W. Baird | Outperform |
| 2021-12-21 | 개시 | H.C. Wainwright | Buy |
| 2021-11-22 | 개시 | Ladenburg Thalmann | Buy |
| 2021-05-04 | 개시 | Jefferies | Buy |
| 2021-05-04 | 개시 | Piper Sandler | Overweight |
| 2021-05-04 | 개시 | SVB Leerink | Outperform |
모두보기
Onkure Therapeutics Inc 주식(OKUR)의 최신 뉴스
OnKure Therapeutics, Inc.(NasdaqGM: OKUR) added to S&P Global BMI Index - marketscreener.com
OnKure Therapeutics, Inc. (OKUR) Stock Price History & Data - Traders Union
Insiders' US$16.6m Investments In Red Following OnKure Therapeutics' US$19m Dip In Market Value - simplywall.st
OnKure management will hold one-on-one investor meetings in New York - Stock Titan
OnKure (OKUR) Session: Ends Up by 0.25% at $3.94 in the Latest Reading; Key Range: Traders Can Monitor the $3.74-$4.14 Range in Latest TradingChannel Projection - vinanet.vn
Prosight Management, LP Reduces OnKure Therapeutics (OKUR) Stake in Second Quarter - GuruFocus
OnKure Therapeutics (OKUR): ADAR1 reports 5.5% stake as GP falls below 5% - Stock Titan
OnKure Therapeutics (OKUR) investor BVF discloses 8% stake plus 2.15M pre-funded warrants - Stock Titan
OnKure Therapeutics (OKUR) sees 3.6% passive stake reported by Trails Edge - Stock Titan
Oppenheimer Adjusts OnKure Therapeutics PT to $14 From $30, Maintains Outperform Rating - marketscreener.com
Oppenheimer Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Cuts Target Price to $14 - Moomoo
OKUR Q2 2026 Earnings: Narrower-Than-Expected Loss Points to Cost Discipline at Clinical-Stage BiotechEstimate Dispersion - vinanet.vn
OKUR Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates by 43.19%Revenue Recognition Risk - Vinanet
OnKure Reprices Underwater Stock Options to Boost Retention - TipRanks
Prosight entities report 2.4% OnKure Therapeutics (OKUR) stake in 13G/A - Stock Titan
OnKure Therapeutics (OKUR) Holds Steady at $4.14 as Biotech Consolidates Within Tight RangeEarnings Sentiment - dars.gov.et
Onkure Therapeutics Inc (OKUR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
LifeSci Capital Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Maintains Target Price $16 - Moomoo
OnKure Therapeutics has cash runway into 2029 - BizWest
JonesTrading Maintains OnKure Therapeutics(OKUR.US) With Hold Rating - Moomoo
OnKure Therapeutics reports Q2 2026 net loss $15.3M; $176.4M cash runway into 2029 - TradingView
OKUR: IND-enabling PI3Ka programs advance toward 2027 filings, backed by $176M cash runway into 2029 - TradingView
OnKure Therapeutics, Inc. Q2 2026: Net loss $(30.5M) for 6M, EPS $(0.31) — 10-Q Summary - TradingView
OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - The Manila Times
OnKure Therapeutics (Nasdaq: OKUR) raises $150M to fund PI3Kα drugs - Stock Titan
OKUR: Q2 2026 net loss was $15.3M; cash reserves strengthened by $150M private placement - TradingView
OnKure Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
OnKure Therapeutics Rings the Closing Bell - Nasdaq
OnKure Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
OnKure Therapeutics, Inc. Revenue Breakdown – NASDAQ:OKUR - TradingView
OnKure Therapeutics (OKUR) Falls 4.5% to $3.82: Support at $3.63 Faces Key TestAAII Bullish - careplusvn.com
Vivo Capital LLC Invests $7.98 Million in OnKure Therapeutics, Inc. $OKUR - MarketBeat
OKUR Q1 2026 Earnings: Stock Rises Despite Wider-Than-Expected LossAnalyst Coverage Count - careplusvn.com
Onkure Therapeutics Inc (OKUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Onkure Therapeutics Inc (OKUR) Balance Sheet - TradingKey
Onkure Therapeutics Inc (OKUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OKUR|Onkure Therapeutics Inc|Price:4.050|Chg%:-0.070 - TradingKey
Onkure Therapeutics Inc (OKUR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OnKure Therapeutics (OKUR) Slips 1.7% as Shares Test Key Support ZoneSeasonality Effect - careplusvn.com
Onkure Therapeutics Inc (OKUR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Onkure Therapeutics Inc (OKUR) Institutional Confidence - TradingKey
Onkure Therapeutics Inc (OKUR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Onkure Therapeutics Inc (OKUR) Cash Flow - TradingKey
Onkure Therapeutics Inc (OKUR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OKUR Q1 2026 Earnings: Wider-than-expected loss as clinical-stage biotech progresses pipelineBanking Earnings Report - vinanet.vn
Onkure Therapeutics Inc (OKUR) Income Statement - TradingKey
OKUR Options Volatility — NASDAQ:OKUR - TradingView
OKUR Options Chain — NASDAQ:OKUR - TradingView
Price to earnings forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
OnKure Therapeutics (OKUR) Rises 3.6% as Stock Approaches Key Resistance LevelGamma Exposure - careplusvn.com
Price to sales forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
Onkure Therapeutics Inc (OKUR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):